Silexion Therapeutics Reports Positive Preclinical Findings for SIL204

What Happened
On September 28, 2026, Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K under Regulation FD to disclose a press release titled “Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers.” The press release (furnished as Exhibit 99.1) reports positive preclinical data for the company’s candidate SIL204 related to systemic uptake mechanisms in KRAS-driven cancers.

Key Details

• Date of disclosure: September 28, 2026; press release furnished as Exhibit 99.1 to the Form 8-K.
• Topic: Positive preclinical findings for SIL204 demonstrating a mechanism for endogenous systemic uptake.
• Disease focus: KRAS-driven cancers (preclinical stage).
• Filing type: Regulation FD disclosure (Item 7.01) — information incorporated by reference into the 8-K.

Why It Matters
This disclosure informs investors that Silexion’s preclinical work on SIL204 showed encouraging mechanistic results related to systemic uptake in KRAS-driven cancers, a biologically important pathway for drug delivery and activity. While preclinical results are early and not clinical efficacy or safety data, the announcement can be material for investors tracking the company’s pipeline progress, development milestones, and potential value drivers. The 8-K ensures the information was publicly released and accessible via the furnished press release.